Perspective Therapeutics (CATX) Income from Continuing Operations (2010 - 2026)

Perspective Therapeutics has disclosed Income from Continuing Operations across 17 years of filings, most recently posting 26189000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 26189000.0, down 44.08% year-over-year; the trailing twelve-month figure through Mar 2026 was 8012000.0 (up 90.72% YoY), and the FY2024 annual result was 79989000.0, down 99.44% from the prior year.
• Income from Continuing Operations came in at 26189000.0 for Q1 2026 at Perspective Therapeutics, down from 66145000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 66145000.0 in Q4 2025 to a low of 41828000.0 in Q4 2024.
• The 5-year median for Income from Continuing Operations is 11214000.0 (2024), against an average of 9477176.47.
• Across the five-year window, Income from Continuing Operations tumbled 3087.33% in 2024 and jumped 258.14% in 2025, its largest moves.
• Perspective Therapeutics' Income from Continuing Operations stood at 7335000.0 in 2022, then tumbled by 149.12% to 18273000.0 in 2023, then sank by 128.91% to 41828000.0 in 2024, then surged by 258.14% to 66145000.0 in 2025, then tumbled by 139.59% to 26189000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 26189000.0 (Q1 2026), 66145000.0 (Q4 2025), and 25969000.0 (Q3 2025), per Business Quant data.